Recall Register

Drug recall: Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL), Solution for Intravenous Infusion, Sterile Solution, 100 mL Single…

Class III FDA enforcement event 85054. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impurities during stability testing.

Class III, in the words of FDA

a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences

Breckenridge Pharmaceutical, Inc started this drug recall on 24 Feb 2020. The firm address in the FDA record is in Berlin, CT. FDA put the recall in Class III. FDA event 85054 has 1 product record. The first FDA enforcement report date is 4 Mar 2020. The record gives the status Terminated, with the termination date 31 Aug 2020.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the U.S.

Recalling firm

Breckenridge Pharmaceutical, Inc, Berlin, CT.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 85054: product records
Recall numberProductQuantityClassStatusReport date
D-1063-2020Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL), Solution for Intravenous Infusion, Sterile Solution, 100 mL Single - Dose Vial per Carton, Rx Only, Distributed by: Breckenridge Pharmaceutical, Inc., Boca Raton, FL 33487, Manufactured by: Pharmaceutics International, Inc., Hunt Valley, MD 21031, NDC 51991-064-98.900 VialsClass IIITerminated4 Mar 2020

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class III: The lowest of the three FDA recall classes.

The event in context

Drug events that started in 2020
342
Share of these events in Class III
21%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
21

Other events of the firm

Other FDA enforcement events of Breckenridge Pharmaceutical, Inc
InitiatedProduct (first record)TypeClassRecords
4 Jun 2026Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical EurDrugClass II2
21 Apr 2026Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., MartorDrugClass II1
24 Nov 2025Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals EuDrugClass II2
9 Oct 2025Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 5199DrugClass II1
8 Aug 2025Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa PharmaceuticaDrugClass II1
25 Jul 2025Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa PharmaceuticaDrugClass II1
15 Jul 2025Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. DrugClass II1
30 Jun 2025Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. MarDrugClass II1
14 Apr 2025Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe,DrugClass II2
26 Mar 2025Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa PharmaceuticaDrugClass II1

Breckenridge Pharmaceutical, Inc: all 21 events

Official channels

Cite this page

Recall Register. FDA enforcement event 85054. https://recallregister.com/fda/iii/85054/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the U.S.
What quantity of product is in FDA event 85054?
The FDA record gives this quantity: 900 Vials
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2020 have the same class?
21% of the 342 drug events that started in 2020 are in Class III.